Current status of SPAP – Swiss Patient Access Program
Current status of the SPAP project (Swiss Patient Access Program):
- The project has now been running for a little over a year
- The processes have been thoroughly tested and are well established
- 24 experts have made themselves available to handle cases
- An initial interim evaluation of the cases submitted to date is being prepared and will be presented at the SOHC
- A third pharmaceutical company will join the programme at the beginning of 2025, with more companies in the pipeline.
Pro memoria: SPAP enables hardship cases to be reassessed in the processing of KVV Art. 71 and to provide such patients with access to OLU therapies. The prerequisite is the prior approval of two independent experts appointed by the SGMO. You can find more information about SPAP here.
At this year’s SOHC (20-22 November 2024, CCB Basel), various meetings on SPAP are also planned, including an exchange with the case-evaluating experts and an information event for pharmaceutical companies. At the SGMO General Assembly on 20 November 2024, 12:30-13:30 (Room Kairo 1-2, CCB Basel), the board will also provide insight into the first interim evaluation of SPAP.
Important information for treating oncologists: If you have hardship cases, please contact the SPAP secretariat: https://www.spap.health/de/
